Oncocyte raises $10.2M in private placement, adds two major transplant centers as customers

Insight Molecular Diagnostics Inc.

Private placement of 3.46M shares at $2.948/share raises ~$10.2M gross; includes participation from strategic partner Bio-Rad.
Proceeds for working capital and general corporate purposes; closing expected October 4, 2024.
Two leading transplant university hospitals in U.S. and Germany adopt GraftAssure research assay for graft damage monitoring.
Submitted Q-Sub to FDA for IVD version of dd-cfDNA test; FDA meeting scheduled for early December 2024.

item 1.01 item 3.02 item 7.01 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.